奥特之母被儿子|99e热国产新地址获取|久久精品国产av高潮|美女网站在线观看视频18|东山岛在哪个市|动漫《妻子参加同学会》|近更新中文字幕2019国语

團隊人員

1.  研究組長：金子兵教授，金老師同時兼任溫州醫科大學研究生院院長。金老師曾在日本留學和工作了8年多，在日本理化學研究所先后做博士后和特聘研究員，日本理化學研究所相當于我國中科院的研究機構。2012年發現iPS制備方法的諾貝爾獎獲得者就是在這個研究所工作，金老師在日本也是從事干細胞方面的研究。金老師于2011年回國，組建自己的實驗室。一直與日本的理化學研究所的科學家，高橋政代保持密切的合作，高橋教授是全球首位用iPS細胞進行臨床試驗的科學獎，2014被Nature評為全球十大杰出科學家。所以我們實驗室是中日聯合視網膜再生醫療實驗室。在學校領導的支持下，2015年溫州醫科大學干細胞研究所正式掛牌成立，金老師任研究所的所長。

2.  工作人員：潘少輝、高美玲、陳雪姣、潘登、孫蘭芳、劉慧、林強、黃秀峰、呂技能、項略、徐小濤、毛建洋

研究方向：

本團隊的研究主要關注視網膜變性疾病，這是一種神經退行性疾病，在全球引起眾多病人的不可逆的視力損傷以及失明。代表性的視網膜變性疾病包括遺傳性視網膜營養不良(IRD)、年齡相關性黃斑變性和糖尿病性視網膜病變。我們致力于闡明RP的疾病機制，轉化實驗室技術以改善臨床治療，并與視網膜專家共同解決關鍵的基本問題。我們實驗室的主要技術包括臨床遺傳學和新的捕獲測序、分子生物學、多能干細胞和分化，以及實驗動物模型（小鼠和獼猴）。

遺傳性視網膜營養不良(IRD)，包括視網膜色素變性（RP）、Stargardt病、錐體營養不良或錐形桿營養不良等一系列單基因視力減退性疾病。常見的表現是視桿細胞和/或視錐細胞的病理變化，視網膜中的特化和光敏神經元。目前，超過165種致病基因與IRD相關，顯示出疾病的極端遺傳異質性，因此使分子診斷在技術上具有挑戰性，因為這需要大量的時間和資源。我們開發了一種定制的捕獲測序策略來全面執行IRD患者的分子診斷，這將改善臨床診斷和患者預后，相關結果發表在Genetic in Medicine上。我們最近發現了常染色體隱性RP的第37個基因SLC7A14，并闡明了其體內和體外的疾病機制，結果發表在Nature Communication上。

年齡相關性黃斑變性（AMD）是一種與年齡有關的退化性黃斑病，引起不可避免的視力喪失。中國的流行率在3％左右，而且隨著年齡的增長，應該會大幅增加。過去幾十年來，人們對了解遺傳因素以及環境因素，開展抗VEGF治療以解決新生血管相關并發癥作出了巨大的努力。就疾病病因而言，視網膜色素上皮（RPE）功能障礙和解體是關鍵病變。我們正在開發使用誘導多能干（iPS）細胞和生物可降解支架的RPE替代療法，相關結果發表在Biomaterials上。

最近，我們首次建立了RP患者來源的體外疾病模型和藥物測試的iPS細胞系，結果發表在PLoS One，Stem Cells Transl Med 等。為該領域的患者特異性iPS應用打開了大門。 我們正在使用這些尖端的，先進的工具在實驗室中進行疾病機制研究。

the Retinal Regenerative Medical Research Group

Team Members

1.       Principle Investigator: Zi-Bing Jin, M.D. & Ph.D.

Professor Jin is the Dean of the Graduate School of Wenzhou Medical University. Jin has studied and worked in Japan for more than eight years and completed postdoctoral training at REKEN and become a JSPS fellow there. The REKEN of Japan is equivalent to the research institute of Chinese Academy of Sciences. The Nobel winner Yamanaka who discovered the iPS preparation method worked at this institute in 2012, and at the same time Jin also worked on stem cells in Dr. Takahashi’s lab in Japan . Jin returned to China in 2011 to set up his own laboratory. Dr. Takahashi has been the world's first scientific conducted clinical trials with iPS cells. In 2014, Dr. Takahashi was award as the Nature's Top Ten Outstanding Scientists by Nature. Therefore, our laboratory is a Sino-Japanese joint retinal regeneration medical laboratory. The Stem Cell Institute of Wenzhou Medical University was formally established in 2015, and Professor Jin is the director of the institute.

2.       Team Staff: Shaohui Pan, Meiling Gao, Xuejiao Chen, Deng Pan, Lanfang Sun, Hui Liu, Qiang Lin, Xiufeng Huang, Jineng Lu, Lue Xiang, Xiaotang Xu, Jianyang Mao.

Scope of Research Proposal

Retinal degeneration (RD) is a group of degenerative diseases occurring in human retina and is the leading cause of inevitable vision loss as well as midway blindness worldwide. The major representative RD includes inherited retinal dystrophy (IRD), age-related macular degeneration (AMD), and diabetic retinopathy (DR). We are dedicating to make efforts on elucidating the disease mechanisms of RP, translating laboratory technology to improve bedside outcome, and solving key basic problems together with retina specialists. The major technologies in our laboratory include clinical genetics and new capture sequencing, molecular biology, pluripotent stem cell & differentiation, experimental animal models (mouse and macaque).

IRD is a group of monogenic, vision-impairing diseases including retinitis pigmentosa (RP), Stargardt's disease, cone dystrophy or cone-rod dystrophy, etc. The common manifestation is a pathological change in rod and/or cone photoreceptor cells, which are the specialized and light-sensitive neurons in the retina. Currently, more than 165 disease-causing genes have been linked to IRD demonstrating the extreme genetic heterogeneity of the disease and therefore making molecular diagnosis technically challenging because it would require a massive commitment of time and resources. We have developed a customized capture sequencing strategy to comprehensively perform molecular diagnosis for IRD patients (PLoS One 2013; Genet Med 2014; Genet Med 2015), which would improve clinical diagnosis and patient outcome. We discovered the 37th gene of autosomal recessive RP, SLC7A14, recently and elucidated its disease mechanism in vitro and in vivo (Nat Commun 2014).

AMD is an age-related degenerative macular disease causing inevitable vision loss. It's prevalence is around 3% in China and supposed to increase significantly with the coming age of ageing. In the past decades, great efforts have been made on understanding genetic predispositions as well as environmental factors, and developing anti-VEGF therapy to solve neovascularization-related complications. In term of the disease etiology, retina pigment epithelium (RPE) dysfunction and disorganization are the key lesions. We are developing RPE replacement therapy using induced pluripotent stem (iPS) cells and bio-degradable scaffolds (Biomaterials 2014).

Recently we for the first time established RP patient-derived iPS cell lines for in vitro disease modeling and drug test (PLoS One 2011; Stem Cells Transl Med 2012), opening the door of patient-specific iPS application in the field. We are keeping on the disease mechanism study using these cutting-edge, state-of-art tools in the laboratory.